Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease

Overview

The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2024

Detailed Description

Dihydromyricetin (DHM), a bioactive flavonoid from an edible plant (ampelopsis grossedentata), is reported to have multiple protective effects against chemical-induced liver injuries. For example, the antioxidant activity and cellular metabolic protective effects of DHM may act via the AMP kinase (AMPK) and nicotinamide adenine dinucleotide (NAD+)-dependent Sirtuin (Sirt)-1 energy regulating pathway. Furthermore, there is accumulating evidence supporting the use of DHM for the treatment of alcohol use disorder and the possible reduction/prevention of alcohol-associated liver disease in animal models. DHM may represent a novel approach to counteract alcohol-induced liver damage and promote alcohol metabolism via changes in hepatocellular bioenergetics and mitochondrial biogenesis driven by the AMPK/Sirt-1/PGC-1α axis. These preclinical data suggest the potential of DHM as a novel therapeutic agent in alcohol-related diseases. However, further study in humans is warranted. While DHM has been used for herbal tea in traditional Chinese medicine for hundreds of years, and there has been a small clinical trial using DHM in China among individuals with non-alcoholic fatty liver disease, there have been no controlled human studies published that have assessed the safety, pharmacokinetics, or optimal dosing of DHM in humans. DHM is marketed as a dietary supplement in the United States and is not regulated by the Food and Drug Administration (FDA) as a drug. Because the FDA has little control over the quality of herbal products such as DHM, it is necessary to quantitatively estimate the potentially active ingredients and the pharmacokinetic (PK) profile with oral administration. The current proposal is designed as a first-in-human Phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of DHM among healthy volunteers using a purified form of DHM from a local cGMP compliant source (Master Herbs, Inc).

Interventions

  • Drug: Dihydromyricetin
    • Dose-escalation and lysine preparation

Arms, Groups and Cohorts

  • Experimental: Cohort 1
    • DHM 300mg x1 dose
  • Experimental: Cohort 2
    • DHM 900mg x1 dose
  • Experimental: Cohort 3
    • DHM 300mg x1 dose + Lysine 140mg x1 dose
  • Experimental: Cohort 4
    • DHM 900mg x1 dose + Lysine 420mg x1 dose

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetics
    • Time Frame: -0.5 (pre-dose), 0 (1st dose), 0.5, 1, 2, 4, 6, 8 (2nd dose), 12, and 24 hours post-dose.
    • serum DHM metabolites will be performed using MRM mass
  • Adverse Events
    • Time Frame: 24 hours post-dose
    • The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 will be used to assess and grade AE severity

Participating in This Clinical Trial

Inclusion Criteria

  • No prior medical history of alcohol use disorder or alcohol-associated liver disease – Between 18-60 years old Exclusion Criteria:

  • Weight below 50kg. – Advanced liver disease – Other acute liver diseases – HIV co-infection – History of pancreatic or biliary disease – Acute illness that would interfere with drug absorption – Pregnancy – Participants who are currently taking drugs with CYP3A4 effects

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Southern California
  • Provider of Information About this Clinical Study
    • Principal Investigator: Brian P. Lee, Assistant Professor of Medicine – University of Southern California
  • Overall Official(s)
    • Brian Lee, MD, Principal Investigator, University of Southern California
  • Overall Contact(s)
    • Brian Lee, MD, 323-442-5576, brian.lee@med.usc.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.